About Xelcis Bio
Building the Delivery Infrastructure for Precision Oncology
Xelcis Bio is developing XELCIS XB, a platform designed to enable cytosolic delivery and increase the probability of success for high-value oncology programs.
SCROLL
Who We Are
Focused on One of Oncology’s Most
Persistent Barriers
Xelcis Bio™ is a biotechnology company focused on solving one of the most persistent challenges in oncology drug development: achieving reliable cytosolic delivery. Many promising therapeutics fail not because the biology is wrong, but because the payload does not reach sufficient cytosolic concentrations to drive meaningful activity.
XELCIS XB is designed to overcome this limitation by helping therapeutic payloads move beyond cellular uptake and into the cytosol, where intracellular targets can be engaged.
Our Mission
Unlocking the Full Potential of Next-Generation Oncology Therapeutics
Our mission is to unlock the full potential of next-generation oncology therapeutics by enabling reliable cytosolic delivery. By addressing a root cause of program failure, we aim to expand the range of actionable targets and improve success rates across multiple therapeutic modalities.
Platform Strategy
Building a Platform, Not Just a Drug
Xelcis is building XELCIS XB as a platform technology that can support multiple programs and partners — enhancing existing assets, enabling difficult intracellular targets, and extending across modalities including targeted protein degradation, biologics, and nucleic acid therapeutics.
Our Approach
Platform Strategy & Development Focus
Our development strategy is focused on generating partner-ready data packages that demonstrate functional activity, translational relevance, and platform applicability across modalities.
Platform Enables Multiple Programs
Enhances existing therapeutic assets limited by delivery.
Expands access to intracellular targets.
Applies across TPD, biologics, and nucleic acid therapeutics.
Reducing Development Risk
Improves probability of biological activity.
Strengthens translational confidence.
Supports more efficient development decisions.
Unlocks value across partner portfolios.
Built for Collaboration
We are engaging pharmaceutical and biotechnology companies to evaluate XELCIS XB as a delivery solution that can enhance programs, enable new targets, and reduce portfolio risk.
Our People
Experienced Leadership
Xelcis Bio™ is led by a team with deep experience in oncology drug development, delivery technologies, and company building — combining scientific, clinical, and strategic expertise. We are supported by advisors and board members with extensive experience across biotechnology, pharmaceutical development, and strategic partnering.
Leadership Team
R. Michael Dudley
Co-Founder, CEO & Director
Qiyong Peter Liu, PhD
Co-Founder, Chief Scientist & VP R&D
Subrata Ghosh, PhD
Director of Biology
Board of Directors
Alan Freidman
Co-Founder & Director, Business Advisor
_edited.png)
Ira S. Weinman, MBA
Independent Director
Cynthia Pussinen, MS
Independent Director
Rayna Lesser Hannaway, CFA
Independent Director
Advisors & Consultants
Dustan Bonnin, CVA, PAg, MBA
Co-Founder & Strategic Advisor
Rick Clemon, CPA, CGMA
Chief Financial Advisor
Candida Fratazzi, MD
Chief Medical Advisor
Sendurai Mani, PhD
Scientific Advisor
Suzanne Vyvoda
Clinical Operations Consultant
Looking Ahead
A Platform for the Next Generation of Oncology
By making cytosolic delivery more reliable and predictable, Xelcis aims to expand what is therapeutically achievable in oncology.
Enable Previously Inaccessible Targets
Targets limited by intracellular access may become actionable when cytosolic delivery is solved.
Improve Success Rates Across Modalities
Addressing delivery as a root cause of attrition may improve the probability of success across therapeutic classes.
Foundational Technology for Partners
XELCIS XB is being built to become core delivery infrastructure for oncology programs that require reliable cytosolic delivery.